PBAC's latest decision on Ramipril with felodipine: Recommended with restriction (2007). Considered for Hypertension in a patient not adequately controlled with either ramipril or felodipine monotherapy.
PBAC outcome
Recommended with restriction
Restricted benefit
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2007
Submissions
1
2007 → 2007
Eligible population
patients not adequately controlled with either ramipril or felodipine monotherapy
Therapy area
Cardiovascular
Line of therapy
Not applicable
Evidence base
RCT
Key trials
Study B1, Study B2, Study B3, Study B4
Comparator
ramipril and felodipine extended release (ER) monotherapies
Economic model
Cost-minimisation
Budget impact
$-45000
Eligible patients/year
10,000
ICER note
Cost-minimisation approach adopted; no ICER calculated